A clinical guide to buprenorphine for dogs and cats: comparing Buprenex, Simbadol, and Zorbium, mapping feline behavioral effects, DEA Schedule III rules, and openFDA reports.

Pain management in veterinary medicine has undergone a major paradigm shift over the past two decades. Today, clinical protocols prioritize preemptive and multimodal analgesia to prevent wind-up pain and improve patient outcomes. Within this clinical framework, buprenorphine has emerged as the most widely used and trusted opioid analgesic in small animal practice, particularly for feline patients.

Buprenorphine’s chemical properties and receptor-binding dynamics make it a highly effective agent for post-operative and acute pain management. However, its clinical application is complicated by the presence of three distinct formulations: Buprenex (off-label human injectable), Simbadol (once-daily veterinary subcutaneous injection), and Zorbium (long-acting veterinary transdermal solution). Each formulation exhibits different pharmacokinetic profiles, labeled indications, and clinical utility. Furthermore, veterinary teams must manage its DEA Schedule III controlled substance status and understand the unique behavioral and physiological responses it triggers in feline patients.

This guide provides a comprehensive, clinical overview of buprenorphine for dogs and cats. We examine its pharmacology, compare the three primary formulations, outline clinical monitoring and feline safety considerations, address DEA compliance workflows, and analyze the FDA's veterinary adverse-event reports.

Receptor Pharmacology and the Ceiling Effect

Buprenorphine is a semi-synthetic, highly lipophilic opioid derivative of the main alkaloid of the opium poppy, thebaine. Its clinical profile is defined by its specific interactions with the host's opioid receptors, which differ significantly from full mu-opioid agonists like morphine, hydromorphone, and fentanyl.

Receptor Binding Profile and Kinetics

Buprenorphine operates under a complex receptor-binding mechanism:

Mu-Opioid Receptors: Buprenorphine is a partial mu-agonist. It binds to mu receptors with extremely high affinity (it binds tightly and is difficult to displace) but exhibits low intrinsic activity (it does not trigger the maximum possible cellular response). Because of this high affinity, buprenorphine can displace full mu-agonists from the receptor. If a dog or cat is receiving a full mu-agonist for severe pain, administering buprenorphine can displace the full agonist, resulting in a sudden reduction in analgesia.
Kappa-Opioid Receptors: Buprenorphine is a kappa-antagonist. By blocking kappa receptors, it avoids the dysphoria and sedative effects often mediated by this receptor class.
Receptor Dissociation: Buprenorphine dissociates (unties) from opioid receptors very slowly. This slow dissociation contributes to its prolonged duration of action compared to short-acting full agonists, and it makes buprenorphine-induced respiratory depression difficult to reverse with naloxone, as the naloxone cannot easily displace the bound buprenorphine.

The Pharmacological Ceiling Effect

A defining characteristic of partial mu-agonists is the ceiling effect. As the dose of buprenorphine increases, both the analgesic efficacy and the side effects (specifically respiratory depression) reach a plateau rather than continuing to climb. With a full mu-agonist such as morphine, hydromorphone, or fentanyl, respiratory depression rises in a linear, dose-dependent fashion until respiratory arrest occurs. Buprenorphine's respiratory depressant effect, by contrast, flattens out at a safe maximum well below the lethal threshold for most patients.

This ceiling is what gives buprenorphine a wider safety margin than full mu-agonists and makes it a strong choice for general-practice anesthesia protocols and outpatient recovery. The trade-off, covered below, is that the ceiling also caps how much analgesia the drug can deliver—so it is not sufficient on its own for severe, multi-hit pain.

Comparing the Three Formulations

In clinical practice, veterinarians choose between three primary oral, injectable, or topical formulations containing buprenorphine. Understanding their differences is essential to selecting the right drug for the right patient.

1. Buprenex (Human Injectable)

Formulation: 0.3 mg/mL buprenorphine hydrochloride solution.
Approval Status: FDA-approved for human use; used off-label in veterinary medicine under the provisions of AMDUCA.
Dosing and Routes: Dosed at 0.01 to 0.03 mg/kg in dogs and cats. It can be administered intravenously (IV), intramuscularly (IM), or via the oral-transmucosal (OTM) route.
Feline Oral-Transmucosal (OTM) Efficacy: Cats possess a unique oral physiology—specifically a high buccal pH—that allows buprenorphine to be absorbed rapidly and completely across the oral mucosa. When Buprenex is squirted into a cat’s mouth, it is absorbed through the gums, bypassing first-pass hepatic metabolism. In cats, OTM administration achieves a bioavailability of approximately 60% to 70%, which is nearly equivalent to subcutaneous injection. This makes it an ideal option for at-home post-operative pain management. In contrast, dogs do not absorb oral-transmucosal buprenorphine reliably; it must be injected IV or IM to achieve predictable analgesia.
Duration: Typically provides 6 to 8 hours of effective pain control.

2. Simbadol (Veterinary Subcutaneous Injection)

Formulation: 1.8 mg/mL high-concentration buprenorphine hydrochloride solution.
Approval Status: FDA-approved (NADA 141-434, originally approved in 2014; now marketed by Zoetis) specifically for use in cats.
Dosing and Route: Administered as a subcutaneous (SC) injection at 0.24 mg/kg once daily. It is approved for up to 3 consecutive days of administration.
Clinical Purpose: Designed specifically to control post-operative pain associated with major feline surgeries (such as spays, neuters, and dental extractions). The high concentration and unique formulation allow for slow systemic absorption, extending the duration of action to a full 24 hours.
Contraindications: Simbadol is approved for cats only. It must not be used in dogs, where the high dose and concentration can cause severe, prolonged sedation and dysphoria.

3. Zorbium (Veterinary Transdermal Solution)

Formulation: 20 mg/mL high-concentration transdermal solution.
Approval Status: FDA-approved (NADA 141-547, manufactured by Elanco, approved January 20, 2022) specifically for use in cats.
Dosing and Route: Applied topically to the skin at the base of the neck. The dosage is based on body weight, delivering a single dose that provides continuous systemic analgesia.
Clinical Purpose: Designed to control post-operative pain associated with surgical procedures in cats. A single topical application provides continuous pain control for approximately 4 days (96 hours), with a clinical onset of action within 1 to 2 hours. This eliminates the need for owners to administer daily injections or oral medications at home, which reduces stress for both the pet and the owner.
Patient Restrictions: Per the FDA label, Zorbium is restricted to cats:
- At least 4 months of age.
- Weighing at least 2.6 lbs (1.2 kg).
- Weighing no more than 16.5 lbs (7.5 kg).
- Zorbium must not be applied to broken or damaged skin, and veterinary staff must wear appropriate personal protective equipment (PPE) during application to prevent accidental human exposure.

Formulation Comparison Summary

Parameter	Buprenex (Off-Label)	Simbadol (FDA-Approved)	Zorbium (FDA-Approved)
Active Conc.	0.3 mg/mL	1.8 mg/mL	20.0 mg/mL
Species	Dogs and Cats	Cats Only	Cats Only
Route	IV, IM, OTM (Cats)	Subcutaneous (SC)	Topical Transdermal
Dosing Interval	Every 6 to 8 hours	Every 24 hours (up to 3 days)	Single dose (4-day duration)
Primary Use	Acute pain, short-term	Surgical post-op, 24-hr control	Extended surgical post-op, 96-hr control

Clinical Selection Matrix: Choosing the Right Formulation

To help veterinary teams choose the appropriate formulation, the clinical decision-making process should balance patient-specific factors, procedural severity, expected duration of pain, and client capabilities.

Patient and pain profile	Preferred formulation	Reasoning
Dog, any acute or post-op pain	Buprenex IV/IM	Dogs do not absorb oral-transmucosal buprenorphine reliably; Simbadol and Zorbium are cats-only. Dose 0.01–0.03 mg/kg every 6–8 hours.
Cat, mild short-duration pain (<24 h)	Buprenex OTM	Excellent buccal absorption in cats; owner can give 1–2 doses at home. Dose 0.01–0.03 mg/kg every 6–8 hours.
Cat, major surgery, friendly/easy to handle	Simbadol SC	One daily subcutaneous injection gives 24 hours of control for up to 3 days; owner returns for a repeat injection or the cat stays hospitalized.
Cat, major surgery, fractious/unruly or feral	Zorbium transdermal	A single topical application at surgery delivers ~4 days of analgesia with no further handling—ideal when daily injections are unsafe.
Cat, major dental extraction (painful mouth)	Simbadol SC or Zorbium	Bypasses the oral cavity, where OTM dosing is painful and difficult.

Feline Clinical Scenarios

The Unruly or Fractious Cat (e.g., Feral Spay/Neuter or Aggressive Patient): Handling these patients daily for injections or oral dosing represents a significant safety risk for the veterinary team and the owner. In these cases, Zorbium (transdermal) is the clinical first choice. A single application at the time of surgery provides 4 days of pain control without further handling.
Major Dental Extractions with High Post-Operative Swelling: These cats have painful mouths, and oral-transmucosal (OTM) Buprenex administration is painful and difficult. Simbadol (SC injection) or Zorbium (transdermal) is preferred, bypassing the oral cavity entirely.
Mild, Short-Duration Procedures (e.g., Minor Laceration Repair): These patients only require 12 to 24 hours of pain control. Buprenex OTM is highly appropriate, allowing the owner to administer 1 to 2 doses at home as needed.

Clinical Monitoring and the Feline Opioid Response

Opioids trigger a unique set of behavioral and physiological responses in cats that can alarm owners if they are not prepared. Understanding these expected pharmacodynamic effects is critical to distinguishing normal drug responses from adverse drug reactions.

Dilated Pupils (Mydriasis)

In cats, buprenorphine routinely causes marked mydriasis (dilation of the pupils). This response is mediated by the feline sympathetic nervous system’s reaction to mu-receptor activation. While dogs typically experience miosis (pupil constriction) after opioid administration, cats will develop large, fully dilated pupils that respond slowly to light.

This effect can persist for 12 to 24 hours after Buprenex or Simbadol, and up to 4 days during Zorbium therapy. Owners should be advised to:

Keep the cat in a dimly lit, quiet room during recovery.
Avoid exposing the cat to bright, direct sunlight.
Recognize that the cat’s depth perception and vision may be temporarily altered, making it prone to misjudging jumps.

Behavioral Dysphoria vs. Euphoria

Feline patients on buprenorphine frequently display altered behavioral patterns. These typically fall into two categories:

Euphoria: Characterized by purring, excessive affection, cheek rubbing, kneading, and general contentment. Some cats show a mild increase in playfulness.
Dysphoria: Characterized by restlessness, constant pacing, vocalization (meowing or yowling), irritability, and inability to settle down or sleep. Dysphoric cats may appear agitated or disoriented.

Veterinary staff should distinguish between pain-induced vocalization and drug-induced dysphoria. If a cat is vocalizing but is comfortable when the surgical site is gently palpated, the behavior is likely dysphoria. If the cat tenses, growls, or withdraws when the site is touched, the pain is not controlled, and the multimodal analgesic protocol should be adjusted—often by adding non-opioid options like gabapentin or NSAIDs. For multimodal pain management strategies, refer to our clinical guide on gabapentin for dogs.

Hyperthermia and Bradycardia

Hyperthermia: Cats can develop mild-to-moderate elevations in body temperature (hyperthermia) following buprenorphine administration. This is believed to result from the drug’s effect on the thermoregulatory center in the hypothalamus, combined with increased physical activity from pacing. Rectal temperatures can rise to 103°F–104°F (39.4°C–40.0°C). Temperature should be monitored closely in hospitalized cats; if it exceeds 104.5°F, active cooling measures (removing warm blankets, applying cool water to paw pads) should be initiated.
Bradycardia: Buprenorphine can cause a mild reduction in heart rate (bradycardia) via increased vagal tone. While rarely clinically significant in stable patients, it requires monitoring when buprenorphine is combined with other sedatives that cause bradycardia, such as dexmedetomidine. For details on managing cardiovascular parameters under sedation, see the dexmedetomidine for dogs and cats guide.

Hepatic Metabolism and Safety Limits

Buprenorphine is metabolized primarily by the liver via glucuronidation and CYP450 pathways, and it is excreted in the bile and feces. Because cats have a limited capacity for glucuronide conjugation, they clear buprenorphine slower than dogs.

In dogs and cats with pre-existing hepatic dysfunction or liver disease, buprenorphine clearance is delayed. This leads to prolonged sedation, accumulation of the drug, and increased risk of side effects. For these patients:

Dose intervals for Buprenex should be extended (e.g., every 12 to 24 hours instead of every 8 hours).
Simbadol and Zorbium should be used with extreme caution or avoided in favor of alternative analgesics.
Liver enzymes and clinical sedation scores should be monitored.

DEA Compliance: Schedule III Handling and Audit SOPs

Because buprenorphine is an opioid with potential for human abuse, it is classified as a Schedule III Controlled Substance by the United States Drug Enforcement Administration (DEA). Veterinary practices must adhere to strict security, record-keeping, and disposal protocols to remain compliant with federal law.

Secure Storage and Physical Security

All buprenorphine formulations must be stored in a securely locked cabinet or safe that meets specific federal criteria:

The safe must be constructed of heavy-grade steel and permanently anchored to the building structure (bolted directly to the concrete floor or wall studs).
Only licensed DVMs and designated, credentialed veterinary technicians may hold the keys or know the safe combination.
Key storage must be secure; keys cannot be left in desk drawers or hanging on hooks in the pharmacy area.

Detailed Logbooks and Record Keeping

Every milliliter of buprenorphine ordered, received, administered, dispensed, or wasted must be recorded in a dedicated controlled substance logbook. The log must include:

The date of the transaction.
The patient’s name and ID number.
The client's name.
The starting volume in the vial.
The exact volume administered or wasted (recorded to the hundredth of a milliliter, e.g., 0.12 mL).
The name and signature of the person administering the drug.
The remaining volume in the vial.

Managing Losses and waste

Needle Hub Loss (Dead Space): Every time buprenorphine is drawn from a vial, a small amount of liquid (~0.02 to 0.05 mL) remains in the syringe hub and needle. Over the life of a 10 mL vial, this "dead space loss" can accumulate, leading to a physical volume shortage. This must be recorded as "needle hub loss" or "draw loss" in the logs rather than left unexplained.
Significant Loss and DEA Form 106: If an unexplained shortage occurs that exceeds normal needle hub limits, it must be investigated immediately. If the loss is deemed "significant" under federal guidelines, the clinic must notify the field division office of the DEA in writing within one business day of discovery and complete DEA Form 106 (Report of Theft or Loss of Controlled Substances).
Chemical Destruction: Leftover or contaminated buprenorphine must be chemically denatured (using commercial activated carbon deactivation bags) or sent to an approved reverse distributor for incineration. It cannot legally be squirted down the drain or thrown in the trash.

For the step-by-step clinical protocol for managing inventory audits and investigating safe shortages, see the controlled substance discrepancy investigation workflow.

Analysis of FDA openFDA Adverse-Event Data

To evaluate the safety profile of buprenorphine in clinical practice, we analyzed the FDA Center for Veterinary Medicine's animal drug adverse-event records, accessed through the openFDA database (analysis run date: 2026-07-05).

The search returned 7,288 unique reports where buprenorphine was recorded as an active ingredient. The species breakdown shows a massive feline dominance, confirming its status as the iconic cat analgesic:

Cats: 5,457 reports (74.9%)
Dogs: 1,534 reports (21.0%)
Other (Rabbits, Humans, Unknown): 297 reports (4.1%)

Top 10 Reported Reaction Terms

The table below displays the ten most frequent reaction terms associated with buprenorphine in the database:

Position	Reaction Term	Report Count	Clinical Context and Interpretation
1	Behavioural disorder NOS	999	Reflects drug-induced dysphoria, pacing, and restlessness; particularly in cats.
2	Not eating	781	Direct appetite suppression; common post-surgical or drug-induced response.
3	Dilated pupils	734	Expected pharmacodynamic response in cats (mydriasis); reported as a side effect.
4	Anorexia	631	Decreased appetite; closely linked to "not eating" and post-operative recovery.
5	Lethargy	614	Systemic sedation; expected central nervous system effect.
6	Death	596	Outcome; highly confounded by polypharmacy and severe pre-existing diseases.
7	Hyperactivity	575	Behavioral signal; reflects pacing, agitation, and inability to settle.
8	Dysphoria	521	Specific reaction; vocalization, disorientation, and distress.
9	Vomiting	503	Common gastrointestinal side effect; direct stimulation of the CRTZ.
10	Death by euthanasia	489	Outcome; humane endpoints in severely ill or injured animals.

Interpretation of Safety Signals

A detailed analysis of this data highlights several important clinical points:

The Feline Behavioral Signature: The database is dominated by behavioral reactions: "Behavioural disorder NOS" (999), "Dilated pupils" (734), "Hyperactivity" (575), and "Dysphoria" (521). This signature directly mirrors the feline opioid pharmacology described above. It shows that what owners and veterinary staff report most often are not toxicities, but the visible, expected behavioral changes associated with the drug.
Mortality and the Hospitalized Patient Confound: Across the 7,288 reports, 1,140 reports carried a fatal outcome (653 died, 496 euthanized). In veterinary medicine, buprenorphine is the primary analgesic for critical, high-risk patients—including cats undergoing emergency perineal urethrostomy (PU) for urinary obstruction, dogs with severe polytrauma, or geriatric animals undergoing major dental extractions under prolonged anesthesia. Because these critical patients often receive multiple drugs (sedatives, induction agents, inhalant anesthetics, antibiotics, and fluids), deaths reported in the database are heavily confounded by the patient's critical status and the polypharmacy protocol. These counts represent passive surveillance data and do not prove that buprenorphine caused the deaths.
Zorbium-Specific Discussion: In recent years (2022 to 2026), the database shows a rise in reports matching the uptake of Zorbium transdermal solution. On third-party forums and social media, an active litigation discussion (e.g., references to "Zorbium lawsuits") has emerged, driven by pet owners reporting unexpected deaths in cats after Zorbium application. Clinicians must note that these social media reports are preliminary, uncontrolled, and do not constitute an FDA safety conclusion. The openFDA data shows that Zorbium is highly effective when applied to appropriate candidates (healthy cats undergoing routine surgery), but its long, irreversible duration (96 hours) means that if a cat develops a severe reaction (such as severe hyperthermia or profound anorexia), supportive care (hospitalization, fluid therapy, temperature monitoring) must be maintained until the drug clears.

Frequently Asked Questions

What is the difference between Buprenex, Simbadol, and Zorbium for cats?

While all three contain the same active drug (buprenorphine), they differ in concentration, how they are given, and how long they last. Buprenex is a human injectable used off-label in cats (often in the mouth/gums) that lasts 6 to 8 hours. Simbadol is a high-concentration FDA-approved injection given under the skin that lasts 24 hours. Zorbium is a very high-concentration transdermal liquid applied to the skin at the back of the neck that lasts for 4 days (96 hours).

Why are my cat's pupils dilated and behavior odd after buprenorphine?

Dilated pupils (mydriasis), pacing, purring, restlessness, and vocalization are common, expected responses to buprenorphine in cats. These behaviors, sometimes called "opioid dysphoria" or "opioid euphoria," are caused by how the cat's brain processes opioids. They are not signs of poisoning, but you should keep your cat in a quiet, dimly lit room to help them recover safely.

Is buprenorphine safer than other opioids because of its ceiling effect?

Yes, buprenorphine has a "ceiling effect" on respiratory depression. This means that after a certain dose, increasing the amount of drug does not cause further breathing depression, making it much safer than full opioids like morphine or fentanyl. However, it can still cause sedation, slow heart rates, and high body temperatures, so patients must still be monitored closely.

Can buprenorphine be used in cats with liver disease?

Buprenorphine is metabolized by the liver, so cats with liver disease clear the drug much slower than healthy cats. This can lead to drug accumulation, prolonged sedation, and an increased risk of side effects. If buprenorphine must be used, veterinarians typically use the short-acting Buprenex at extended intervals rather than the long-acting Simbadol or Zorbium formulations.

Sources

FDA CVM. Simbadol (buprenorphine hydrochloride injection, NADA 141-434) Freedom of Information summary. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/926
FDA CVM. Zorbium (buprenorphine transdermal solution, NADA 141-547) Freedom of Information summary. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11847
FDA CVM. FDA Approves First Transdermal Buprenorphine for Use in Cats (Zorbium, approved January 20, 2022). https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-transdermal-buprenorphine-control-post-surgical-pain-cats
DailyMed. Zorbium (buprenorphine transdermal solution) full prescribing label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c00709bf-12fd-40fc-9cff-7a7e7390fcb8
DailyMed. Simbadol (buprenorphine hydrochloride injection) full prescribing label. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3395bb4d-e032-4c16-81cf-d8f364033bb8
American Animal Hospital Association (AAHA). 2022 AAHA Pain Management Guidelines for Dogs and Cats. https://www.aaha.org/resources/2022-aaha-pain-management-guidelines-for-dogs-and-cats/
Merck Veterinary Manual. Opioid Analgesics: Pharmacology and Clinical Use. https://www.merckvetmanual.com/pharmacology/systemic-pharmacotherapeutics-of-the-nervous-system/opioids
Plumb's Veterinary Drug Handbook. Buprenorphine monograph. https://www.plumbs.com/
FDA Center for Veterinary Medicine. openFDA Animal & Veterinary Adverse Event API (report-level adverse-event records, 1987–2026; analysis run date 2026-07-05). https://open.fda.gov/apis/animalandveterinary/

Vet Med Guide

Buprenorphine for Dogs and Cats: Buprenex, Simbadol, Zorbium, and the FDA Data